CD96 and prostate cancer: Furthermore, CD96−/− mice are resistant to MCA-induced fibrosarcoma and experimental lung metastasis modeled by injecting B16F10 melanoma cells (77), and blocking CD96 with a mAb inhibits experimental metastases in three different models (B16F10 melanoma, 3LL lung carcinoma, and RM-1 prostate cancer) (63).